T3 MGen Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
3
T3 MGen General Information
Description
Developer of immune cell modulation technology designed for immunotherapeutic research targeting inflammatory and infectious diseases. The company's platform utilizes algorithms, small molecule screening, and formulation of chemically synthesized and plant-based compounds, enabling researchers to identify therapeutic candidates and support the development of treatments for various diseases.
Contact Information
Website
www.t3mgen.comCorporate Office
- Bangalore Bioinnovation Centre
- Bangalore Helix Biotech Park, Electronics City Phase-1
- Bangalore, Karnataka 560100
- India
Corporate Office
- Bangalore Bioinnovation Centre
- Bangalore Helix Biotech Park, Electronics City Phase-1
- Bangalore, Karnataka 560100
- India
T3 MGen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Accelerator/Incubator | 01-Jan-2022 | Completed | Startup |
T3 MGen Comparisons
Industry
Financing
Details
T3 MGen Competitors (6)
One of T3 MGen’s 6 competitors is Immuneel, a Venture Capital-Backed company based in Bengaluru, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immuneel | Venture Capital-Backed | Bengaluru, India | ||||
| Nkure Therapeutics | Venture Capital-Backed | Bangalore, India | ||||
| ImmunoACT | Venture Capital-Backed | Navi Mumbai, India | ||||
| GentiBio | Venture Capital-Backed | Cambridge, MA | ||||
| ImmunitoAI | Venture Capital-Backed | Bengaluru, India |
T3 MGen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
T3 MGen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
T3 MGen Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bangalore Bioinnovation Centre | Accelerator/Incubator | Minority | ||
| AIC-SEED | Accelerator/Incubator | Minority | ||
| BITS BioCyTiH Foundation | Accelerator/Incubator | Minority |
T3 MGen FAQs
-
When was T3 MGen founded?
T3 MGen was founded in 2021.
-
Where is T3 MGen headquartered?
T3 MGen is headquartered in Bangalore, India.
-
What is the size of T3 MGen?
T3 MGen has 5 total employees.
-
What industry is T3 MGen in?
T3 MGen’s primary industry is Drug Discovery.
-
Is T3 MGen a private or public company?
T3 MGen is a Private company.
-
What is T3 MGen’s current revenue?
The current revenue for T3 MGen is .
-
Who are T3 MGen’s investors?
Bangalore Bioinnovation Centre, AIC-SEED, and BITS BioCyTiH Foundation have invested in T3 MGen.
-
Who are T3 MGen’s competitors?
Immuneel, Nkure Therapeutics, ImmunoACT, GentiBio, and ImmunitoAI are some of the 6 competitors of T3 MGen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
